Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorTuncer, Seref Bugra
dc.contributor.authorCelik, Betul
dc.contributor.authorErciyas, Seda Kilic
dc.contributor.authorErdogan, Ozge Sukruoglu
dc.contributor.authorGultaslar, Busra Kurt
dc.contributor.authorOdemis, Demet Akdeniz
dc.contributor.authorAvsar, Mukaddes
dc.contributor.authorSen, Fatma
dc.contributor.authorSaip, Pinar Mualla
dc.contributor.authorYazici, Hulya
dc.date.accessioned2024-03-13T12:08:10Z
dc.date.available2024-03-13T12:08:10Z
dc.date.issued2024en_US
dc.identifier.citationTuncer, S. B., Celik, B., Erciyas, S. K., Erdogan, O. S., Gültaslar, B. K., Odemis, D. A., ... & Yazici, H. (2024). Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing. Pathology-Research and Practice, 254, 155075.en_US
dc.identifier.issn03440338
dc.identifier.urihttps://doi.org/10.1016/j.prp.2023.155075
dc.identifier.urihttps://hdl.handle.net/20.500.12294/4077
dc.description.abstractHereditary Breast and Ovarian Cancer (HBOC) syndrome is characterized by an increased risk of developing breast cancer (BC) and ovarian cancer (OC) due to inherited genetic mutations. Understanding the genetic variants associated with HBOC is crucial for identifying individuals at high risk and implementing appropriate preventive measures. The study included 630 Turkish OC patients with confirmed diagnostic criteria of The National Comprehensive Cancer Network (NCCN) concerning HBOC. Genomic DNA was extracted from peripheral blood samples, and targeted Next-generation sequencing (NGS) was performed. Bioinformatics analysis and variant interpretation were conducted to identify pathogenic variants (PVs). Our analysis revealed a spectrum of germline pathogenic variants associated with HBOC in Turkish OC patients. Notably, several pathogenic variants in BRCA1, BRCA2, and other DNA repair genes were identified. Specifically, we observed germline PVs in 130 individuals, accounting for 20.63% of the total cohort. 76 distinct PVs in genes, BRCA1 (40 PVs), BRCA2 (29 PVs), ATM (1 PV), CHEK2 (2 PVs), ERCC2 (1 PV), MUTYH (1 PV), RAD51C (1 PV), and TP53 (1PV) and also, two different PVs (i.e., c.135–2 A>G p.? in BRCA1 and c.6466_6469delTCTC in BRCA2) were detected in a 34-year-old OC patient. In conclusion, our study contributes to a better understanding of the genetic variants underlying HBOC in Turkish OC patients. These findings provide valuable insights into the genetic architecture of HBOC in the Turkish population and shed light on the potential contribution of specific germline PVs to the increased risk of OC. © 2024 Elsevier GmbHen_US
dc.language.isoengen_US
dc.publisherElsevier GmbHen_US
dc.relation.ispartofPATHOLOGY RESEARCH AND PRACTICEen_US
dc.identifier.doi10.1016/j.prp.2023.155075en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBRCA1/BRCA2en_US
dc.subjectGermline Mutationsen_US
dc.subjectHBOCen_US
dc.subjectMultigene Panelsen_US
dc.subjectNGSen_US
dc.subjectOvarian Canceren_US
dc.titleGermline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencingen_US
dc.typearticleen_US
dc.departmentTıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.authorid0000-0002-8919-0482en_US
dc.identifier.volume254en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.institutionauthorYazici, Hulya
dc.authorwosidGSK-8744-2022en_US
dc.authorscopusid7102511789en_US
dc.identifier.wosqualityQ2en_US
dc.identifier.wosWOS:001164343600001en_US
dc.identifier.scopus2-s2.0-85182582146en_US
dc.identifier.pmid38219492en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster